Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.

Approximately one third of patients with non-small cell lung cancer have unresectable stage IIIA or stage IIIB disease; combined cytotoxic chemotherapy and radiation therapy delivered concurrently has been established as the standard treatment for such patients. Despite many clinical trials that tested several different radiochemotherapy combinations, it seems that a plateau of efficiencies at the acceptable risk of complications has been reached. Clinical studies indicate that the improved efficacy of radiochemotherapy is associated with the radiosensitizing effects of chemotherapy. Improvement of outcomes of this combined modality by developing novel radiosensitizers is a viable therapeutic strategy. In addition to causing cell death, ionizing radiation also induces a many-faceted signaling response, which activates numerous prosurvival pathways that lead to enhanced proliferation in the endothelial cells and increased vascularization in tumors. Radiation at doses used in the clinic activates cytoplasmic phospholipase A2, leading to increased production of arachidonic acid and lysophosphatidylcholine. The former is the initial step in the generation of eicosanoids, while the later is the initial step in the formation of lysophosphatidic acid, leading to the activation of inflammatory pathways. The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) is member of the insulin superfamily of receptor tyrosine kinases. The EML4-ALK fusion gene appears unique to lung cancer and signals through extracellular signal regulated kinase and phosphoinositide 3-kinase. Heat shock protein 90 (Hsp90) is often overexpressed and present in an activated multichaperone complex in cancer cells, and it is now regarded as essential for malignant transformation and progression. In this review we focus on radiosensitizing strategies involving the targeting of membrane phospholipids, EML4-ALK, and Hsp90 with specific inhibitors and briefly discuss the combination of radiation with antivascular agents.

[1]  S. Hartmann,et al.  Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. , 2013, Cancer letters.

[2]  Jing Wang,et al.  Cox-2 in non-small cell lung cancer: a meta-analysis. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[3]  A. Shaw,et al.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. , 2013, Cancer discovery.

[4]  Namshin Kim,et al.  Investigation of Radiation-induced Transcriptome Profile of Radioresistant Non-small Cell Lung Cancer A549 Cells Using RNA-seq , 2013, PloS one.

[5]  Manway Liu,et al.  The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth , 2013, Molecular Cancer Therapeutics.

[6]  E. Vokes,et al.  New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Nicholas G Zaorsky,et al.  ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK , 2013, Molecular Cancer Therapeutics.

[8]  R. Roskoski,et al.  Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. , 2013, Pharmacological research.

[9]  Cyrus Chargari,et al.  Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation. , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[11]  Benjamin P. C. Chen,et al.  Effect of PF-02341066 and radiation on non-small cell lung cancer cells , 2012, Oncology reports.

[12]  D. de Ruysscher,et al.  Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. , 2012, Cancer treatment reviews.

[13]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[14]  P. Ellis,et al.  Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. , 2012, Critical reviews in oncology/hematology.

[15]  D. Proia,et al.  Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib , 2012, Molecular Cancer Therapeutics.

[16]  G. Blumenschein.  Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC) , 2012, Investigational New Drugs.

[17]  A. Linkous,et al.  Novel radiosensitizing anticancer therapeutics. , 2012, Anticancer research.

[18]  B. Slotman,et al.  Combining angiogenesis inhibition and radiotherapy: a double-edged sword. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[20]  T. Stinchcombe,et al.  Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. , 2012, The oncologist.

[21]  K. Stephans.  Stereotactic body radiotherapy for stage I non–small cell lung cancer , 2012, Cleveland Clinic Journal of Medicine.

[22]  R. Huddart,et al.  The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage , 2012, PloS one.

[23]  J. Soh,et al.  Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. , 2012, Lung cancer.

[24]  M. Flentje,et al.  Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia , 2012, Cancer biology & therapy.

[25]  G. Trinchieri.  Cancer and inflammation: an old intuition with rapidly evolving new concepts. , 2012, Annual review of immunology.

[26]  Tony Taldone,et al.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. , 2012, Biochimica et biophysica acta.

[27]  Paul Workman,et al.  HSP90 inhibition: two-pronged exploitation of cancer dependencies. , 2012, Drug discovery today.

[28]  N. Lin,et al.  HSP90 as a platform for the assembly of more effective cancer chemotherapy. , 2012, Biochimica et biophysica acta.

[29]  G. Simon,et al.  Antiangiogenic agents in the management of non-small cell lung cancer , 2012, Cancer biology & therapy.

[30]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[31]  W. Franklin,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[32]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[33]  O. Dalesio,et al.  Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Meuillet,et al.  Identification and development of mPGES-1 inhibitors: where we are at? , 2011, Future medicinal chemistry.

[35]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[36]  William Pao,et al.  ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.

[37]  Y. Bang,et al.  The potential for crizotinib in non-small cell lung cancer: a perspective review , 2011, Therapeutic advances in medical oncology.

[38]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[39]  D. Hallahan,et al.  Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature , 2011, PloS one.

[40]  Bengt Bergman,et al.  Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. , 2011, European journal of cancer.

[41]  K. Robison,et al.  The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models , 2011, Oncogene.

[42]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[43]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[44]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[45]  P. Baas,et al.  Chemoradiation therapy in nonsmall cell lung cancer , 2011, Current opinion in oncology.

[46]  S. Senan,et al.  Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer , 2011, Current opinion in oncology.

[47]  Benjamin Movsas,et al.  Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. , 2011, Clinical lung cancer.

[48]  A. Shaw,et al.  Targeting Anaplastic Lymphoma Kinase in Lung Cancer , 2011, Clinical Cancer Research.

[49]  H. Nishimasu,et al.  Crystal structure of autotaxin and insight into GPCR activation by lipid mediators , 2011, Nature Structural &Molecular Biology.

[50]  Sunil Krishnan,et al.  Targeting inflammatory pathways for tumor radiosensitization. , 2010, Biochemical pharmacology.

[51]  A. Iafrate,et al.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[53]  Y. Yatabe,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[54]  S. Elledge,et al.  The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.

[55]  A. Linkous,et al.  Cytosolic phospholipase A2 as a mediator of disease pathogenesis , 2010, Cellular microbiology.

[56]  D. Hallahan,et al.  Cytosolic Phospholipase A2 and Lysophospholipids in Tumor Angiogenesis , 2010, Journal of the National Cancer Institute.

[57]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[58]  A. Raza,et al.  Pericytes and vessel maturation during tumor angiogenesis and metastasis , 2010, American journal of hematology.

[59]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[60]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[61]  J. Bradley,et al.  The treatment of early-stage disease. , 2010, Seminars in radiation oncology.

[62]  W. Curran,et al.  Combined modality therapy for stage III non-small-cell lung cancer. , 2010, Seminars in radiation oncology.

[63]  M. Jensen,et al.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction , 2010, British Journal of Cancer.

[64]  F. Paris,et al.  Plasma membrane signaling induced by ionizing radiation. , 2010, Mutation research.

[65]  G. Prestwich,et al.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three‐dimensional lung cancer xenograft model , 2010, Cancer.

[66]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[67]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[68]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Yiling Lu,et al.  Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. , 2009, Cancer cell.

[70]  M. Backlund,et al.  Targeting the eicosanoid pathway in non-small-cell lung cancer , 2009, Expert opinion on therapeutic targets.

[71]  Suresh Senan,et al.  Radiotherapy for lung cancer: clinical impact of recent technical advances. , 2009, Lung cancer.

[72]  J. Morrow,et al.  A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[73]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[74]  D. Hallahan,et al.  Cytosolic Phospholipase A2: Targeting Cancer through the Tumor Vasculature , 2009, Clinical Cancer Research.

[75]  P. Reddanna,et al.  Eicosanoids in inflammation and cancer: the role of COX-2 , 2009, Expert review of clinical immunology.

[76]  M. Weiser-Evans,et al.  Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. , 2009, Cancer research.

[77]  S. P. Herbert,et al.  Activation of Cytosolic Phospholipase A2-α as a Novel Mechanism Regulating Endothelial Cell Cycle Progression and Angiogenesis* , 2009, Journal of Biological Chemistry.

[78]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[79]  D. Hallahan,et al.  Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium , 2008, Cell Death and Differentiation.

[80]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[81]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[82]  G. Shapiro,et al.  Heat shock protein 90 inhibition in lung cancer. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[83]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[84]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[85]  L. Pearl,et al.  The Hsp90 molecular chaperone: an open and shut case for treatment. , 2008, The Biochemical journal.

[86]  I. Szumiel.  Intrinsic Radiation Sensitivity: Cellular Signaling is the Key , 2008, Radiation research.

[87]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[88]  Sriram Krishnamoorthy,et al.  Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.

[89]  Paul Workman,et al.  Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.

[90]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[91]  Guang-qian Zhou,et al.  The performance of a bone-derived scaffold material in the repair of critical bone defects in a rhesus monkey model. , 2007, Biomaterials.

[92]  K. Camphausen,et al.  Inhibition of Hsp90: A Multitarget Approach to Radiosensitization , 2007, Clinical Cancer Research.

[93]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[94]  P. Fisher,et al.  Radiation-induced cell signaling: inside-out and outside-in , 2007, Molecular Cancer Therapeutics.

[95]  W. Moolenaar,et al.  Regulation and biological activities of the autotaxin-LPA axis. , 2007, Progress in lipid research.

[96]  Y. Kishi,et al.  Autotaxin Is Overexpressed in Glioblastoma Multiforme and Contributes to Cell Motility of Glioblastoma by Converting Lysophosphatidylcholine TO Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.

[97]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[98]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[99]  G. Reynolds,et al.  Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. , 2005, Blood.

[100]  D. Zander,et al.  Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. , 2005, Archives of pathology & laboratory medicine.

[101]  D. Fishman,et al.  LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). , 2005, Gynecologic oncology.

[102]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[103]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[104]  Matthew Meyerson,et al.  Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.

[105]  C. Clelland,et al.  Overexpression of cyclooxygenase-2 in non-small cell lung cancer. , 2004, Respiratory medicine.

[106]  R. Kolesnick,et al.  Raft ceramide in molecular medicine , 2003, Oncogene.

[107]  H. Choy,et al.  Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.

[108]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[109]  R. Mikkelsen,et al.  Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms , 2003, Oncogene.

[110]  S. Chakraborti.  Phospholipase A2 isoforms: a perspective , 2003 .

[111]  R. Schmidt-Ullrich,et al.  Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1 , 2003, Radiation research.

[112]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[113]  J. Shelhamer,et al.  85-kDa cPLA2 plays a critical role in PPAR-mediated gene transcription in human hepatoma cells , 2002 .

[114]  A. Hölscher,et al.  Prognostic Significance of Cyclooxygenase 2 mRNA Expression in Non-Small Cell Lung Cancer , 2002, Annals of surgery.

[115]  Y. S. Kim,et al.  Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. , 2001, Cancer research.

[116]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[117]  R. Schmidt-Ullrich,et al.  Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. , 2001, Cancer research.

[118]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[119]  I. Gibbs,et al.  Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. , 2000, International journal of radiation oncology, biology, physics.

[120]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[121]  M. Moskowitz,et al.  Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2 , 1997, Nature.

[122]  P. Dent,et al.  Inactivation of Raf-1 by a Protein-tyrosine Phosphatase Stimulated by GTP and Reconstituted by G Subunits (*) , 1996, The Journal of Biological Chemistry.

[123]  M. Polymeropoulos,et al.  Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. , 1996, Biochemical and biophysical research communications.

[124]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[125]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[126]  Te Vuong,et al.  Past, present, and future of radiotherapy for the benefit of patients , 2013, Nature Reviews Clinical Oncology.

[127]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[128]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[129]  D. DavidS.ShimmM..  Perez and Brady's Principles and Practice of Radiation Oncology , 2008 .

[130]  S. Chakraborti.  Phospholipase A(2) isoforms: a perspective. , 2003, Cellular signalling.

[131]  J. Shelhamer,et al.  85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[132]  A. Korotaeva,et al.  Effect of lysophosphatidylcholine on transmembrane signal transduction. , 1998, Biochemistry. Biokhimiia.

[133]  N. Tonks.  Protein tyrosine phosphatases and the control of cellular signaling responses. , 1996, Advances in pharmacology.

[134]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[135]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .